Emergency Intensive Care Medicine Department, Zibo 148 Hospital, China RongTong Medical Healthcare Group Co. Ltd, Zibo, Shandong Province, 255000, PR China.
Zibo Vocational Institute College of Medical Technology, Zibo, Shandong Province, 255000, PR China.
Future Med Chem. 2024;16(9):905-924. doi: 10.4155/fmc-2024-0010. Epub 2024 Apr 16.
Cancer as a devastating malignancy, seriously threatens human life and health, but most chemotherapeutics have long been criticized for unsatisfactory therapeutic efficacy due to drug resistance and severe off-target toxicity. Pyrimidines, including fused pyrimidines, are privileged scaffolds for various biological cancer targets and are the most important class of metalloenzyme carbonic anhydrase inhibitors. Pyrimidine-sulfonamide hybrids can act on different targets in cancer cells simultaneously and possess potent activity against various cancers, revealing that hybridization of pyrimidine with sulfonamide is a promising approach to generate novel effective anticancer candidates. This review aims to summarize the recent progress of pyrimidine-sulfonamide hybrids with anticancer potential, covering papers published from 2020 to present, to facilitate further rational design of more effective candidates.
癌症作为一种毁灭性的恶性肿瘤,严重威胁着人类的生命和健康,但由于耐药性和严重的脱靶毒性,大多数化疗药物的治疗效果一直受到批评。嘧啶类化合物,包括稠合嘧啶类化合物,是各种生物癌症靶点的优势骨架,也是最重要的一类金属酶碳酸酐酶抑制剂。嘧啶-磺酰胺杂合体可以同时作用于癌细胞中的不同靶点,对各种癌症具有强大的活性,这表明嘧啶与磺酰胺的杂化是产生新型有效抗癌候选物的有前途的方法。本综述旨在总结具有抗癌潜力的嘧啶-磺酰胺杂合体的最新进展,涵盖了 2020 年至今发表的论文,以促进更有效的候选物的进一步合理设计。